Fig. 4.
Pharmacokinetic model estimates across treatments. Comparison of individual CL (left) and V 1 (right) estimates in patients who received olaratumab as a single agent or in combination with either PTX and CP or Dox. CL clearance, CP carboplatin, Dox doxorubicin, PTX paclitaxel, V 1 central volume of distribution